

1 **UNDIAGNOSED CHILDREN INSURANCE COVERAGE**

2 **AMENDMENTS**

3 2019 GENERAL SESSION

4 STATE OF UTAH

5 **Chief Sponsor: Steve Eliason**

6 Senate Sponsor: David G. Buxton

8 **LONG TITLE**

9 **General Description:**

10 This bill requires the state Medicaid program and Public Employees' Benefit and
11 Insurance Program to cover exome sequence testing.

12 **Highlighted Provisions:**

13 This bill:
14 ▶ defines terms; and
15 ▶ requires the state Medicaid program and Public Employees' Benefit and Insurance
16 Program to cover exome sequence testing for certain enrollees.

17 **Money Appropriated in this Bill:**

18 None

19 **Other Special Clauses:**

20 None

21 **Utah Code Sections Affected:**

22 ENACTS:

23 **26-18-25**, Utah Code Annotated 1953

24 **49-20-419**, Utah Code Annotated 1953

26 *Be it enacted by the Legislature of the state of Utah:*

27 Section 1. Section **26-18-25** is enacted to read:

28 **26-18-25. Coverage of exome sequence testing.**

29 (1) As used in this section, "exome sequence testing" means a genomic technique for
30 sequencing the genome of an individual for diagnostic purposes.

31 (2) The Medicaid program shall reimburse for exome sequence testing:

32 (a) for an enrollee who:

33 (i) is younger than 21 years of age; and

34 (ii) who remains undiagnosed after exhausting all other appropriate diagnostic-related
35 tests;

36 (b) performed by a nationally recognized provider with significant experience in exome
37 sequence testing;

38 (c) that is medically necessary; and

39 (d) at a rate set by the Medicaid program.

40 Section 2. Section **49-20-419** is enacted to read:

41 **49-20-419. Coverage of exome sequence testing.**

42 (1) As used in this section, "exome sequence testing" means a genomic technique for
43 sequencing the genome of an individual for diagnostic purposes.

44 (2) Beginning July 1, 2019, the program shall provide coverage for exome sequence
45 testing:

46 (a) for a covered individual within the state risk pool who:

47 (i) is younger than 21 years of age; and

48 (ii) who remains undiagnosed after exhausting all other appropriate diagnostic-related
49 tests;

50 (b) performed by a nationally recognized provider with significant experience in exome
51 sequence testing;

52 (c) that is medically necessary; and

53 (d) at a rate set by the program.